ClinicalTrials.gg
TerminatedNCT06677307REWRITEUpdated Apr 17, 2026

A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110

A Phase 1/2 interventional study of KRRO-110 in Alpha-1 Anti-trypsin Deficiency and AATD, sponsored by Korro Bio, Inc.. Terminated at 5 sites in 2 countries. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by Korro Bio, Inc. · Phase 1/2, Interventional, and Treatment

How we know

Why this study was terminated
The study was terminated for business decision reasons.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in alpha 1-Antitrypsin Deficiency with a site in Australia — 7 open to participants now, 8 under way, 2 of them phase 3. alpha 1-Antitrypsin Deficiency · Australia.

Enrollment
14th of 18
42 · median 70
Started
2025
the only one that year
Phase 1/2
5 of 18
4 open now
Registered
15th of 18
by date
Lead sponsor
1 of 18
Korro Bio, Inc.

Among the 18 studies in alpha 1-Antitrypsin Deficiency with a site in Australia, this one is the 14th largest by enrollment, is the only one that started in 2025, is one of 5 in phase 1/2, and was the 15th registered.

alpha 1-Antitrypsin Deficiency

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

Browse alpha 1-Antitrypsin Deficiency studies →

Open to participants now

7 of the 18 studies in alpha 1-Antitrypsin Deficiency with a site in Australia are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in alpha 1-Antitrypsin Deficiency with a site in Australia, or all of them as a file.
02

Study summary

The purpose of this first-in human (FIH) study is to assess the safety, tolerability, and pharmacokinetics (PK) of single and multiple doses of KRRO-110 in both healthy adult participants and in clinically stable patients with Alpha-1 antitrypsin deficiency (AATD).

03

Conditions studied

  • Alpha-1 Anti-trypsin Deficiency
  • AATD
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

Part A SAD cohort Inclusion Criteria (Healthy Volunteers)

  • Adult male or female participants, 18 to 65 years of age
  • Documented PiMM genotype
  • Participants who are willing to and able to provide signed written

PiZZ Genotype (Part A SAD and Part B MAD cohorts) Inclusion Criteria (PiZZ Genotype)

  • Adult male or female participants 18 to 70 years of age (inclusive)
  • Documented PiZZ genotype
  • Baseline blood total AAT level \< 11 µM/L

Exclusion Criteria:

Exclusion Criteria (Healthy Volunteers)

  • Female participant of or male participant that is unable or unwilling to use an approved, reliable means of
  • (BMI) > 32 or \< 18.5 kg/m2
  • History or current clinical evidence of hepatic disease
  • Evidence of active infection
  • History of medical condition(s), eg, advance cardiac disease, current or recent , organ transplantation, or other illness
  • Serology result indicative of any exposure (past or active) to , , or (HIV)
  • Respiratory or other acute illness within 8 weeks
  • Tobacco use of any kind within 6 months

Exclusion Criteria (PiZZ Genotype)

  • Female participant of childbearing potential or male participant that is unable or unwilling to use an approved, reliable means of contraception
  • BMI > 32 or \< 18.5 kg/m2 or weight > 90 kg
  • History of \< 35%
  • History or current clinical evidence of advanced hepatic disease and/or pulmonary disease
  • Use of an experimental therapy except KRRO-110 within 6 months or 5 half-lives for the experimental therapy, whichever is greater
  • Tobacco use of any kind within 6 months
  • Use of conventionally dosed AAT augmentation therapy within 5 half-lives
  • Serology result consistent with exposure to HIV, or serology consistent with active hepatitis B or hepatitis C infection
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Arm 1: KRRO-110 (Part A and Part B)

    KRRO-110 is an RNA editing oligonucleotide encapsulated in a lipid nanoparticle (LNP) administered by intravenous (IV) infusion as a single dose in Part A (SAD), multi-dose in Part B (MAD).

    Drug: KRRO-110

  • Placebo comparator
    Arm 2: Placebo (Part A only)

    Placebo, IV administration

    Drug: KRRO-110

Interventions

  • DrugKRRO-110

    KRRO-110 drug product, IV

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability

    Type, frequency, and severity of treatment-emergent adverse events (TEAEs)

    Time frame: From Day 1 to Day 43 in the SAD and from Day 1 to Day 85 in the MAD

Secondary outcomes

  1. Pharmacokinetics (PK) of KRRO-110

    PK profile of KRRO-110 including maximum blood concentration (Cmax)

    Time frame: Day 1 to Day 43 (SAD), and Day 1 to Day 85 (MAD)

  2. Pharmacodynamics (PD) of KRRO-110

    PD profile of KRRO-110 based on change from Baseline in alpha-antitrypsin (AAT) enzyme levels at all measured timepoints (PiZZ participants only).

    Time frame: Day 1 to Day 43 (SAD), and Day 1 to Day 85 (MAD)

  3. Pharmacokinetics (PK) of KRRO-110

    PK profile of KRRO-110 half-life (t1/2), area under the concentration-time curve (AUC), and trough level (MAD cohorts only).

    Time frame: Day 1 to Day 43 (SAD), and Day 1 to Day 85 (MAD)

07

Study locations

5 sites
  • The Prince Charles Hospital
    Brisbane, Queensland 4032, Australia
  • Nucleus Network Pty Ltd
    Melbourne, Victoria 3004, Australia
  • St. Vincent's Hospital Melbourne
    Melbourne, Victoria 3065, Australia
  • New Zealand Clinical Research
    Auckland, New Zealand
  • New Zealand Clinical Research
    Christchurch, New Zealand
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2025 to primary completion in Oct 2025, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2024
First posted
Nov 6, 2024
StartActual
Jan 13, 2025
Primary completionActual
Oct 31, 2025
CompletionActual
Dec 15, 2025
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06677307
Lead sponsor
Korro Bio, Inc.
Responsible party
Sponsor
First posted
Nov 6, 2024
Start date
Jan 13, 2025
Primary completion
Oct 31, 2025
Completion
Dec 15, 2025
Last update
Apr 17, 2026

Study contacts

Study Director
study director · Korro Bio, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion